Darolutamide (DARO) tolerability from extended follow up and treatment response in the phase 3 ARAMIS trial.Karim Fizazi,Neal D. Shore,Matthew Raymond Smith,Teuvo Tammela,Christopher Michael Pieczonka,Jeanny B. Aragon-Ching,David Morris,Marie-Aude Le Berre,Shankar Srinivasan,Oana Petrenciuc,Christian Zurth,Iris KussJOURNAL OF CLINICAL ONCOLOGY(2021)引用 5|浏览11暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要